Symbol Lookup from Yahoo Finance

Trending Tickers

Symbol	Name	Last Price	Change	Change %
SOL-USD	Solana USD	241.34	+20.68	+9.37%
INTC	Intel Corporation	21.49	+1.82	+9.25%
BTC-USD	Bitcoin USD	103,318.03	+533.37	+0.52%
^GSPC	S&P 500	5,996.66	+59.32	+1.00%
^DJI	Dow Jones Industrial Average	43,487.83	+334.70	+0.78%
^IXIC	NASDAQ Composite	19,630.20	+291.91	+1.51%
ETH-USD	Ethereum USD	3,296.07	-119.20	-3.49%
TRUMP4733780-USD	Trump47 USD	0.00	+0.00	+72.82%
XRP-USD	XRP USD	3.17	-0.08	-2.56%
BTCT	BTC Digital Ltd.	8.26	+3.50	+73.53%
SOL-CAD	Solana CAD	349.30	+29.93	+9.37%
TD.TO	TORONTO-DOMINION BANK	83.13	+3.53	+4.43%
^RUT	Russell 2000	2,275.88	+9.09	+0.40%
FMCC	Freddie Mac	6.10	+1.27	+26.29%
SOL-EUR	Solana EUR	234.76	+20.12	+9.37%
XCN18679-USD	Onyxcoin USD	0.01	+0.00	+36.48%
XRP-EUR	XRP EUR	3.08	-0.08	-2.56%
MRNA	Moderna, Inc.	34.06	+0.30	+0.89%
NVO	Novo Nordisk A/S	78.69	-4.38	-5.27%
CRKN	Crown Electrokinetics Corp.	0.1250	+0.0453	+56.84%
^SPX	S&P 500 INDEX	5,996.66	+59.32	+1.00%
GOEV	Canoo Inc.	1.3500	-0.1600	-10.60%
BTC-EUR	Bitcoin EUR	100,501.22	+518.83	+0.52%
SBUX	Starbucks Corporation	95.13	+0.70	+0.74%
FXAIX	Fidelity 500 Index Fund	208.30	+2.07	+1.00%

Related News

Stock market today: Dow leads weekly stock market rally ahead of Trump inauguration

Investors are appraising Trump policies' likely impact on stocks on the last trading day before the inauguration.

Yahoo Finance 22 hours ago

^IXIC

^GSPC
Medicare to negotiate prices on 15 drugs, including Ozempic

Medicare seeks to negotiate prices on 15 drugs, including Novo Nordisk's (NVO) GLP-1 weight-loss drugs Ozempic and Wegovy, in new talks. Yahoo Finance senior health reporter Anjalee Khemlani explains the process and the range of other drugs on this new list from pharmaceutical giants Pfizer (PFE), AstraZeneca (AZN), Merck (MRK) To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Luke Carberry Mogan.

Yahoo Finance Video 16 hours ago

PFE

MRK
Intel stock pops on report of supposed mystery buyer

Intel (INTC) shares are on the rise after SemiAccurate reported that a mystery company is trying to acquire the company as a whole. Alexandra Canal and Josh Lipton break down the report and why it's sending Intel shares higher on Market Domination. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Naomi Buchanan.

Yahoo Finance Video 19 hours ago

INTC
Trump's expected crypto regulation clarity sends bitcoin soaring

Bitcoin (BTC-USD) is yet again trading above the $100,000 mark amid reports that crypto is an early priority for the incoming Trump administration. Delta Blockchain Fund founder and general partner Kavita Gupta joins Catalysts with Seana Smith to discuss the crypto industry heading into Trump's return to the White House. Gupta says the crypto community is relieved that Trump is prioritizing crypto regulation. "There is a big feeling of, 'Thank God we are no more in a gray area,'" she says. "It feels like now, every institution, every government, every country's president is talking about it, which is absolutely great." "We do want to protect retail customers. We want to work within the government bounds ... the clarity on the regulations is and should be the first priority," Gupta adds. Watch the video above to learn about Gupta's expectations for Trump's administration to bolster the US's global standing within the crypto space, crypto initial public offering (IPO) opportunities, and downside risks to bitcoin's rise. To watch more expert insights and analysis on the latest market action, check out more Catalysts here. The post was written by Naomi Buchanan.

Yahoo Finance Video 18 hours ago

BTC-USD
How Trump can deliver on big promises made to the crypto industry

Trump made a lot of promises to crypto enthusiasts in 2024 as he pledged to make the United States the "crypto capital of the planet." Can he deliver on all of them in 2025?

Yahoo Finance 20 hours ago

BTC-USD

COIN
Novo Nordisk's Ozempic & Wegovy in 2027 Medicare price talks

Novo Nordisk's (NVO) GLP-1 weight loss drugs, Ozempic and Wegovy, will be targeted in the next round of Medicare price negotiations in 2027, along with 13 other medications. Seana Smith and Brad Smith break down the details on Morning Brief. The last round of the Inflation Reduction Act (IRA) negotiations gave Medicare an average 22% price reduction for the drugs on this list. With $41 billion in annual Medicare spending on these drugs, the implications for healthcare costs — especially obesity treatments — are massive. However, questions loom around regulatory decisions under a new Trump administration, adding complexity to future outcomes. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. This post was written by Josh Lynch

Yahoo Finance Video 21 hours ago

NONOF

NVO
What Trump is planning for day one — and what could matter most for investors

Donald Trump and his allies are promising a "blizzard" of activity on Jan. 20, with perhaps 100 executive actions to be signed within hours of Trump's swearing-in.

Yahoo Finance 22 hours ago

^DJI
S&P 500 futures, Trump and crypto, TikTok ban: 3 Things

Stock futures (ES=F, NQ=F, YM=F) move higher in Friday's extended hours, putting the S&P 500 (^GSPC) on pace for its best trading week since the 2024 election. Bitcoin (BTC-USD) rises back above $100,000 on reports of President-elect Donald Trump prioritizing crypto by proposing a new advisory council when he retakes office. The Supreme Court has yet to announce its decision and proposed options for the proposed ban on TikTok just two days out from the law's deadline. Many speculate on whether Trump could extend the deadline in his reentry into the White House. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. This post was written by Luke Carberry Mogan.

Yahoo Finance Video 23 hours ago

YM=F

NQ=F
3 Brilliant Growth Stocks That Can Outperform the S&P 500 by 2030

The bull market has pushed the S&P 500 up 22% over the past year, but historically, the popular barometer has averaged about 10% returns annually. To help you in your search, three Motley Fool contributors believe Uber Technologies (NYSE: UBER), MercadoLibre (NASDAQ: MELI), and Cava Group (NYSE: CAVA) have the makings of long-term winners that can outperform the broader market over the next five years. John Ballard (Uber Technologies): Uber stock is up 162% since bottoming out in 2022, but the stock's flat performance over the past year sets up a great buying opportunity.

Motley Fool 8 minutes ago

^GSPC

MELI
Billionaire Bill Ackman Thinks Donald Trump Could Make These 2 Stocks Big Winners -- and Both Are Already Up Over 6X in the Last 12 Months

Billionaire Bill Ackman isn't as much of an activist investor as he used to be. Federal National Mortgage Association (OTC: FNMA) (commonly known as Fannie Mae) and Federal Home Loan Mortgage Corporation (OTC: FMCC) (commonly known as Freddie Mac) are government-sponsored enterprises (GSEs). It takes an act of Congress to create a GSE.

Motley Fool 2 hours ago

FMCC

FNMA
Is Novo Nordisk Stock a Buy?

It hasn't been a great period for investors in Novo Nordisk (NYSE: NVO) despite its ongoing status as one of the pharmaceutical industry's apex competitors in the field of cardiometabolic drugs. Over the last five years, its trailing-12-month revenue grew by 109%, reaching $39.3 billion, thanks to its portfolio of potent drugs for cardiometabolic illnesses like diabetes and obesity. For the company to continue to grow at the same pace it has been recently, its blockbuster drugs, specifically its weight loss drug Wegovy, need to continue to retain a sizable share of the market.

Motley Fool 2 hours ago

NVO
History Says the Nasdaq Will Soar in 2025: 1 Artificial Intelligence (AI) Growth Stock to Buy Before It Does

Historical trends suggest that 2025 should be another great year for the Nasdaq.

Motley Fool 2 hours ago

COMP

NVDA
The Average American Retires at 62. Buying These 3 Investments Now Could Make Your Retirement Much More Comfortable

Investing can be a lifesaver for workers struggling to accumulate enough money to retire comfortably.

Motley Fool 3 hours ago

^GSPC

KO
AMD's Struggling Gaming Business Could Take Another Hit This Year

A lot is going right for Advanced Micro Devices (NASDAQ: AMD) right now. The gaming business is another story. AMD's gaming revenue crashed 69% year over year in the third quarter of 2024 to just $462 million.

Motley Fool 3 hours ago

AMD

NVDA
2 Magnificent Vanguard ETFs I'm Buying and Holding for Decades

If you're looking for a simple way to generate wealth in the stock market with little effort, you can't go wrong with an exchange-traded fund (ETF). An S&P 500 ETF tracks the S&P 500 (SNPINDEX: ^GSPC), meaning it includes all the stocks within the index. The Vanguard S&P 500 ETF (NYSEMKT: VOO) can be a particularly smart investment because of its low expense ratio of just 0.03%.

Motley Fool 3 hours ago

^GSPC
Where Will Apple Stock Be in 5 Years?

A strong market backdrop has lifted Apple (NASDAQ: AAPL) even further. Apple is known for selling popular hardware devices. Five years ago in fiscal 2019, 82% of Apple's total revenue came strictly from products.

Motley Fool 4 hours ago

AAPL

^GSPC
Wall Street's Greatest Dividend Stock -- a Small-Cap Company 99% of Investors Have Never Heard of -- Is the Cheapest It's Been in Over a Decade

This magnificent company has been paying a continuous dividend to its shareholders since 1816.

Motley Fool 4 hours ago

YORW

^GSPC
The Best Investing Move as Trump Takes Over: Wait and See

Financial markets will be watching eagerly to see how much of the president-elect’s ambitious agenda is implemented.

Barrons.com 4 hours ago

^GSPC
Is Palantir Stock a Buy in 2025 After Its 340% Gain in 2024? Wall Street Analysts Have a Surprising Answer

Shareholders of Palantir Technologies (NASDAQ: PLTR) just had a fantastic year. In fact, only six stocks in the S&P 500 have a higher percentage of sell ratings than Palantir, and the median price target of $39 per share implies a 45% downside from its current price of $71. What makes that especially surprising is that Palantir has already fallen by 16% from its record high in recent weeks.

Motley Fool 4 hours ago

^GSPC
The Less Fortunate Hope to Benefit, Too

Readers weigh in on the 2025 Roundtable, the 2024 Roundtable report card, insurance stocks, and the Federal Reserve’s interest-rate cuts.

Barrons.com 9 hours ago

^GSPC

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Trending Tickers

Related News

Stock market today: Dow leads weekly stock market rally ahead of Trump inauguration

Medicare to negotiate prices on 15 drugs, including Ozempic

Intel stock pops on report of supposed mystery buyer

Trump's expected crypto regulation clarity sends bitcoin soaring

How Trump can deliver on big promises made to the crypto industry

Novo Nordisk's Ozempic & Wegovy in 2027 Medicare price talks

What Trump is planning for day one — and what could matter most for investors

S&P 500 futures, Trump and crypto, TikTok ban: 3 Things

3 Brilliant Growth Stocks That Can Outperform the S&P 500 by 2030

Billionaire Bill Ackman Thinks Donald Trump Could Make These 2 Stocks Big Winners -- and Both Are Already Up Over 6X in the Last 12 Months

Is Novo Nordisk Stock a Buy?

History Says the Nasdaq Will Soar in 2025: 1 Artificial Intelligence (AI) Growth Stock to Buy Before It Does

The Average American Retires at 62. Buying These 3 Investments Now Could Make Your Retirement Much More Comfortable

AMD's Struggling Gaming Business Could Take Another Hit This Year

2 Magnificent Vanguard ETFs I'm Buying and Holding for Decades

Where Will Apple Stock Be in 5 Years?

Wall Street's Greatest Dividend Stock -- a Small-Cap Company 99% of Investors Have Never Heard of -- Is the Cheapest It's Been in Over a Decade

The Best Investing Move as Trump Takes Over: Wait and See

Is Palantir Stock a Buy in 2025 After Its 340% Gain in 2024? Wall Street Analysts Have a Surprising Answer

The Less Fortunate Hope to Benefit, Too